Concord Drugs Ltd — Important, 20-11-2025: Company Update

Concord Drugs' board has approved the allotment of 31.75 lakh equity shares at ₹36.30 each, raising ₹11.53 crore through a preferential issue previously greenlit by shareholders. Additionally, the board approved the allotment of 20.25 lakh convertible warrants at ₹36.30 per warrant. The company has already received ₹1.84 crore as 25% upfront consideration for these warrants, which are convertible into equity shares within 18 months upon full payment. This strategic move aims to strengthen the company's capital base and provides potential for future equity infusion.